Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel Micellar in Metastatic Castration-resistant Prostate Cancer
NCT04629781Phase 1Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- May 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Docetaxel micellar in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Dose-limiting toxicity at 3 weeks. Started May 2021; status: terminated.
02
Drugs
Docetaxel micellar
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04629781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629781.